A biotech drug used to treat inherited high cholesterol that last year saw its price reduced will soon only be available at that lower price. Thousand Oaks, California-based Amgen said Thursday that ...
Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...
These results highlight Repatha's ability to reduce the residual risk for CV events particularly in high-risk patients with limited treatment options. One analysis showed the addition of Repatha to ...
Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...
For all the talk about new opportunities for consumers to make their own healthcare decisions, much remains out of their control. Nowhere is that more evident than in the prescription drug market, ...
The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...
SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...
New research shows that Amgen’s Repatha, part of a new class of treatments that dramatically lower cholesterol known as PCSK9 inhibitors, decreased the amount of plaque in patients with heart ...
HOUSAND OAKS, Calif., Amgen today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels with ...
THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback